Bristol Myers Squibb (CELG-RI) Accumulated Expenses (2009 - 2019)

Bristol Myers Squibb (CELG-RI) has 11 years of Accumulated Expenses data on file, last reported at $5.9 billion in Q1 2019.

• Accumulated Expenses for Q1 2019 came in at $5.9 billion, up 5.3% year-over-year; the trailing twelve-month figure through Mar 2019 was $5.9 billion (up 5.3% YoY), and the FY2018 annual result was $6.5 billion, up 7.9% from the prior year.
• Accumulated Expenses retreated to $5.9 billion in Q1 2019 per CELG-RI's latest filing, from $6.5 billion in the prior quarter.
• Over five years, Accumulated Expenses peaked at $6.5 billion in Q4 2018 and troughed at $1.8 billion in Q1 2015.
• A 5-year average of $4.8 billion and a median of $5.1 billion in 2017 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2015 and 2016: Accumulated Expenses slipped 10.32% in 2015, then surged 140.7% in 2016.
• A 5-year view of Accumulated Expenses shows it stood at $4.7 billion in 2015, then climbed by 11.25% to $5.3 billion in 2016, then climbed by 14.1% to $6.0 billion in 2017, then gained by 7.9% to $6.5 billion in 2018, then fell by 9.75% to $5.9 billion in 2019.
• Business Quant data shows CELG-RI's Accumulated Expenses at $5.9 billion in Q1 2019, $6.5 billion in Q4 2018, and $5.9 billion in Q3 2018.